Minocycline

Generic Name: Minocycline

Brand Names: Amzeeq, Arestin, Dynacin, Minocin, Minolira, Solodyn, Ximino, Zilxi

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₇N_₃O_₇

CAS Number: 10118-90-8

Unique Ingredient Identifier: FYY3R43WGO

Background: Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.
...

Indication: Oral and topical minocycline are indicated to treat inflammatory lesions of acne vulgaris. Subgingival microspheres are indicated as an adjunct treatment in the reduction of pocket depth in adults with periodontitis. Oral and intravenous formulations are indicated to treat infections of susceptible microorganisms. These include rickettsiae, Mycoplasma pneumo...

Associated Conditions: Bartonellosis, Brucellosis, Campylobacter fetus, Chancroid, Cholera (Disorder), Conjunctivitis, Inclusion, Granuloma Inguinale, Lymphogranuloma Venereum, Nongonococcal urethritis, Periodontitis, Plague, Psittacosis, Q Fever, Relapsing Fever, Respiratory Tract Infections (RTI), Rickettsia Infections, Rickettsialpox, Rocky Mountain Spotted Fever, Trachoma, Tularemia, Typhus infections, Inflammatory lesions

Associated Therapies: -

Clinical Trials

Enoxaparin and/or Minocycline in Acute Stroke

Not Applicable

Terminated

Conditions: Acute Ischemic Stroke

Interventions: Drug: Enoxaparin
Drug: Minocycline

First Posted Date: 2009-02-04

Last Posted Date: 2016-04-29

Lead Sponsor: NYU Langone Health

Target Recruit Count: 6

Registration Number: NCT00836355

Locations: 🇺🇸
New York University Langone Medical Center, New York, New York, United States
🇺🇸
Bellevue Hospital Center, New York, New York, United States

Minocycline for the Treatment of Early-Phase Schizophrenia

Phase 3

Completed

Conditions: Negative and Cognitive Symptoms in Schizophrenia

Interventions: Drug: Minocycline
Drug: Placebo (200 mg/day)

First Posted Date: 2008-08-12

Last Posted Date: 2008-08-12

Lead Sponsor: Shalvata Mental Health Center

Target Recruit Count: 70

Registration Number: NCT00733057

Locations: 🇮🇱
The Emotion-Cognition Research Center, The Shalvata Mental Health Care Center, P.O.B. 94., Hod-Hasharon, Israel

Minocycline in Clinically Isolated Syndromes (CIS)

Phase 3

Completed

Conditions: Clinically Isolated Syndromes
Early Single Relapse of Multiple Sclerosis

Interventions: Drug: Placebo
Drug: Minocycline

First Posted Date: 2008-04-25

Last Posted Date: 2017-02-27

Lead Sponsor: Dr. Luanne Metz

Target Recruit Count: 142

Registration Number: NCT00666887

Locations: 🇨🇦
Fraser Health Multiple Sclerosis Clinic, Burnaby, British Columbia, Canada
🇨🇦
UBC Hospital, Vancouver, British Columbia, Canada
🇨🇦
CHUM Notre-Dame, Montreal, Quebec, Canada

and more 9 locations

Antibiotic Study for Dental Implants

Phase 3

Completed

Conditions: Periodontitis

Interventions: Drug: Minocycline HCl

First Posted Date: 2008-04-21

Last Posted Date: 2011-12-12

Lead Sponsor: OraPharma

Target Recruit Count: 44

Registration Number: NCT00662532

Locations: 🇺🇸
JJCPPW Investigational Site, Seattle, Washington, United States

Minocycline in Primary Sclerosing Cholangitis (PSC)

Phase 1

Completed

Conditions: Primary Sclerosing Cholangitis

Interventions: Drug: Minocycline

First Posted Date: 2008-03-07

Last Posted Date: 2010-12-07

Lead Sponsor: Mayo Clinic

Target Recruit Count: 16

Registration Number: NCT00630942

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Study of a Neuroprotective Drug to Limit the Extent of Damage From an Ischemic Stroke

Phase 1

Completed

Conditions: Stroke, Acute

First Posted Date: 2008-03-07

Last Posted Date: 2012-01-13

Lead Sponsor: David Hess, MD

Target Recruit Count: 60

Registration Number: NCT00630396

Locations: 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Minocycline and Perfusion Pressure Augmentation in Acute Spinal Cord Injury

Phase 1

Completed

Conditions: Spinal Cord Injuries

Interventions: Drug: placebo
Procedure: SCPP augmentation
Procedure: SCPP control
Drug: Minocycline

First Posted Date: 2007-11-16

Last Posted Date: 2013-03-18

Lead Sponsor: University of Calgary

Target Recruit Count: 52

Registration Number: NCT00559494

Locations: 🇨🇦
Foothills Medical Centre, Calgary, Alberta, Canada

Minocycline to Prevent Acute Kidney Injury After Cardiac Surgery

Not Applicable

Completed

Conditions: Kidney Failure, Acute
Acute Kidney Insufficiency

Interventions: Drug: minocycline
Drug: placebo

First Posted Date: 2007-11-12

Last Posted Date: 2017-12-22

Lead Sponsor: Tarek M. El-Achkar

Target Recruit Count: 40

Registration Number: NCT00556491

Locations: 🇺🇸
Saint Louis University, Saint Louis, Missouri, United States
🇺🇸
Montefiore Medical Center, Bronx, New York, United States

Open-Label Trial of the Use of Minocycline in the Treatment of Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Minocycline

First Posted Date: 2007-09-27

Last Posted Date: 2020-03-10

Lead Sponsor: State University of New York - Downstate Medical Center

Target Recruit Count: 14

Registration Number: NCT00536042

Locations: 🇺🇸
SUNY Downstate Medical Center, Brooklyn, New York, United States

Study of NPL-2003 in Adolescents With Obsessive Compulsive Disorder (OCD)

Phase 2

Terminated

Conditions: Obsessive Compulsive Disorder

First Posted Date: 2007-08-13

Last Posted Date: 2012-04-27

Lead Sponsor: Neuropharm

Target Recruit Count: 6

Registration Number: NCT00515255

Locations: 🇺🇸
New York State Psychiatric Institute, Columbia University, New York, New York, United States
🇺🇸
University Hospitals Case Medical Center, Cleveland, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy